Archived explainer. For the current picture see today's RARE page.
Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?
ULTRAGENYX PHARMACEU (RARE) is up +5.03% in the latest session. Our newswire has captured 3 stories on RARE across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Ultragenyx Pharmaceutical (RARE) shares rose 5.03% to close at $16.70. The primary driver for the move was a presentation at the UBS Global Biopharma Conference, where management outlined 2027 financial targets and operational outlooks.
What Happened
The company participated in the UBS Global Biopharma Conference on November 16, 2026. During the session, executives, including founder Emil Kakkis, discussed the firm's strategic direction and upcoming milestones. A key catalyst for investor interest was the announcement that the UK Medicines and Healthcare products Regulatory Agency accepted the marketing authorisation application for rebisufligene etisparvovec.
On the sell side, Guggenheim lowered its price target on the stock to $24 from $35 while maintaining a Buy rating. Leerink Partners also maintained a Buy rating with a $33 price target. These actions reflect a mixed but generally positive sentiment among analysts regarding the company's long-term potential, despite the recent valuation adjustments.
What The Data Shows
Fundamentals indicate a market cap of $1.6 billion for a company that remains unprofitable, with trailing twelve-month earnings per share of negative $5.18. Revenue grew 15.8% over the same period, though the net margin stands at negative 71.8%. The stock has a beta of 0.36 and trades within a 52-week range of $12.73 to $39.89.
Recent trading activity shows the stock gained 8.2% over the last eight sessions, moving from $15.43 to $16.70. The 52-week tape recorded 17 fresh highs and one fresh low on November 17, 2026. Insider activity over the last 90 days includes three sales totaling $128,000, with no buys recorded. The most recent insider sale was filed on October 19, 2026, by CFO Howard Horn. Congressional disclosures show two buys and no sells in the same period, with the most recent filing on October 12, 2026.
What To Watch
Investors will monitor the company's upcoming participation in other investor conferences as it continues to outline its operational outlook. The market will also watch how the stock reacts to the UK regulatory acceptance and whether the recent price target adjustments from major banks influence broader institutional positioning.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RARE by the numbers
The headlines behind the move
Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM ESTCompany ParticipantsEmil Kakkis - Founder,...
Ultragenyx Pharmaceutical Inc. at UBS Global Biopharma Conference Transcript
More on RARE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RARE move explainers: 2026-11-18 · 2026-10-07 · 2026-09-22 · 2026-09-18 · 2026-09-17 · 2026-09-04 · 2026-09-03